New Data on Ceftaroline, a Novel, Broad-Spectrum Cephalosporin in Development for Complicated Skin and Skin Structure Infections (cSSSI) and Community Acquired Pneumonia (CAP)
WASHINGTON, Oct. 27, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) presented a detailed analysis of CANVAS I, a globally conducted, multi-center, Phase III clinical trial, at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy / Infectious Diseases Society of America 46th Annual Meeting (ICAAC / IDSA) in Washington, DC. The results of this 702 patient study demonstrated that ceftaroline monotherapy achieved its primary endpoint of non-inferiority versus the combination of vancomycin and aztreonam in the treatment of complicated skin and skin structure infections (cSSSI).(1)
Forest also presented eighteen abstracts on data from preclinical studies that demonstrate the activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA), multi-drug resistant Streptococcus pneumoniae (MDRSP) and many gram-negative pathogens in both in vitro and in vivo models of infection.
Results of the CANVAS I study presented on Sunday show that
ceftaroline-treated patients had a clinical cure rate of 91.1% compared to
a vancomycin-plus-aztreonam clinical cure rate of 93.3% at the test of cure
(TOC) visit in the clinically evaluable population (CE). In the
modified-intent-to-treat (MITT) population, ceftaroline-treated patients
had a clinical cure rate of 86.6% compared to a vancomycin-plus-aztreonam
clinical cure rate of 85.6%. The study was de
|SOURCE Forest Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved